The ratio of leptin to adiponectin can be used as an index of insulin resistance

Metabolism: Clinical and Experimental

Volumn 57, Issue 2, 2008, Pages 268-273

  Oda, Naohisa ^a   Imamura, Shigeo ^a   Fujita, Takashi ^a   Uchida, Yuka ^a   Inagaki, Kazumichi ^a   Kakizawa, Hiroaki ^a   Hayakawa, Nobuki ^a   Suzuki, Atsushi ^a   Takeda, Jun ^b   Horikawa, Yukio ^b   Itoh, Mitsuyasu ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; LEPTIN; METFORMIN; PIOGLITAZONE;

ADULT; ARTICLE; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADIPONECTIN; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 38049075329     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.09.011     Document Type: Article

References (22)

1. Matsuzawa Y., Funahashi T., and Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocyte-derived bioactive substance. Ann NY Acad Sci 892 (1999) 146-154
2. Kamohara S., Burcelin R., Halaas J.L., Friedman J.M., and Charron M.J. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 (1997) 374-377
3. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
4. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
5. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
6. Satoh N., Naruse M., Usui T., Tagami T., Suganami T., Yamada K., et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27 (2004) 2488-2490
7. Kotani K., Sakane N., Saiga K., and Kurozawa Y. Leptin:adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness. Diabetologia 48 (2005) 2684-2686
8. Inoue M., Maehata E., Yano M., Taniyama M., and Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 54 (2005) 281-286
9. Inoue M., Yano M., Yamakado M., Maehata E., and Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 55 (2006) 1248-1254
10. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 (1979) E214-E223
11. Heliovaara M.K., Strandberg T.E., Karonen S.L., and Ebeling P. Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Horm Metab Res 38 (2006) 336-340
12. Xita N., Papassotiriou I., Georgiou I., Vounatsou M., Margeli A., and Tsatsoulis A. The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers. Metabolism 56 (2007) 766-771
13. Ebihara K., Masuzaki H., and Nakao K. Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med 351 (2004) 615-616
14. Kumada M., Kihara S., Ouchi N., Kobayashi H., Okamoto Y., Ohashi K., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
15. Samad F., Uysal K.T., Wiesbrock S.M., Pandey M., Hotamisligil G.S., and Loskutoff D.J. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 96 (1999) 6902-6907
16. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
17. DeFronze R.A., Ferrannini E., and Simonson D.C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus contributions of excessive hepatic glucose production and impaired glucose uptake. Metabolism 38 (1989) 387-395
18. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002) 339-343
19. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
20. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
21. Shikata E., Yamamoto R., Takane H., Shigemasa C., Ikeda T., Otsubo K., et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52 (2007) 117-122
22. Ong C.R., Molyneaux L.M., Constantino M.I., Twigg S.M., and Yue D.K. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 29 (2006) 2361-2364